Role of octreotide in the management of malignant intestinal obstruction;Place de l'octreotide dans le traitement des obstructions digestives tumorales

Medecine et Hygiene

Volumn 55, Issue 2169, 1997, Pages 1337-1338

  Barrelet, L ^a   Mazzocato, C ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

OCTREOTIDE;

ADULT; AGED; CLINICAL ARTICLE; CLINICAL TRIAL; DIGESTIVE SYSTEM CANCER; DRUG EFFICACY; FEMALE; GYNECOLOGIC CANCER; HUMAN; INTESTINE OBSTRUCTION; MALE; SHORT SURVEY; SUBCUTANEOUS DRUG ADMINISTRATION; VOMITING;

EID: 0030926562     PISSN: 00256749     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (6)

1. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996 ; 334 : 246-54.
2. Mercadante S, Spoldi E, Caraceni A, Maddaloni S, SimonettiMT. Octreotide in relieving gastrointestinal symptoms due to bowel obstruction. Palliat Med 1993 ; 7 : 295-9.
3. Pandha HS, Waxman J. Octreotide in malignant intestinal obstruction. Anti-Cancer Drugs 1996 ; 7 (Suppl. 1): 5-10.
4. Mangili G, Franchi M, Mariani A, et al. Octreotide in the management of bowel obstruction in terminal ovarian cancer. Gynecologic Oncology 1996 ; 61 : 345-8.
5. Khoo D, Hall E, Motson R, Riley J, Denman K, Waxman J. Palliation of malignant intestinal obstruction using octreotide. Ear J Cancer 1994 ; 30A : 28-30.
6. Cascinu S, Del Ferro E, Catalano G. A randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy. Br J Cancer 1994 ; 71 : 97-101.